NCT03340506 2026-04-20
Dabrafenib and/or Trametinib Rollover Study
Novartis
Phase 4 Recruiting
Clinical Trials
13 trialsNCT03975829 2026-04-02
Pediatric Long-Term Follow-up and Rollover Study
Novartis
Phase 4 Active not recruiting
NCT07486713 2026-03-20
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Rigel Pharmaceuticals
Phase 4 Recruiting
NCT05342883 2025-09-05
GESTALT
GT Medical Technologies, Inc.
Phase 4 Active not recruiting
NCT05900908 2025-04-10
PATHWAyS
GT Medical Technologies, Inc.
Phase 4 Withdrawn
NCT06047535 2023-09-21
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.
SciClone Pharmaceuticals
Phase 4 Not yet recruiting
NCT00395863 2020-11-05
Multihance at 3 Tesla (3T) in Brain Tumors
Bracco Diagnostics, Inc
Phase 4 Completed
NCT02034799 2018-02-26
Phase IV Bioseal Study in Brain Tumor Surgery
Ethicon, Inc.
Phase 4 Completed
NCT00686725 2017-06-14
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT00376064 2017-03-06
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
Novartis
Phase 4 Completed
NCT02034708 2016-12-30
REMIND
Guerbet
Phase 4 Completed
NCT01756729 2016-03-02
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
NovoCure Ltd.
Phase 4 Terminated
NCT02343081 2015-04-02
Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System
Monte Verde SA
Phase 4 Completed